IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i6d10.1007_s40273-021-01012-x.html
   My bibliography  Save this article

Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare

Author

Listed:
  • Kaying Kan

    (University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Interdisciplinary Centre for Psychopathology and Emotion Regulation)

  • Joran Lokkerbol

    (Trimbos Institute (Netherlands Institute of Mental Health and Addiction))

  • Frederike Jörg

    (University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Interdisciplinary Centre for Psychopathology and Emotion Regulation
    Research Department)

  • Ellen Visser

    (University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center)

  • Robert A. Schoevers

    (University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Interdisciplinary Centre for Psychopathology and Emotion Regulation)

  • Talitha L. Feenstra

    (University of Groningen, Department of Science and Engineering, Groningen Research Institute of Pharmacy
    National Institute for Public Health and the Environment (RIVM))

Abstract

Background The majority of patients with major depressive disorder (MDD) have comorbid mental conditions. Objectives Since most cost-of-illness studies correct for comorbidity, this study focuses on mental healthcare utilization and treatment costs in patients with MDD including psychiatric comorbidities in specialist mental healthcare, particularly patients with a comorbid personality disorder (PD). Methods The Psychiatric Case Register North Netherlands contains administrative data of specialist mental healthcare providers. Treatment episodes were identified from uninterrupted healthcare use. Costs were calculated by multiplying care utilization with unit prices (price level year: 2018). Using generalized linear models, cost drivers were investigated for the entire cohort. Results A total of 34,713 patients had MDD as a primary diagnosis over the period 2000–2012. The number of patients with psychiatric comorbidities was 24,888 (71.7%), including 13,798 with PD. Costs were highly skewed, with an average ± standard deviation cost per treatment episode of €21,186 ± 74,192 (median €2320). Major cost drivers were inpatient days and daycare days (50 and 28% of total costs), occurring in 12.7 and 12.5% of episodes, respectively. Compared with patients with MDD only (€11,612), costs of patients with additional PD and with or without other comorbidities were, respectively, 2.71 (p

Suggested Citation

  • Kaying Kan & Joran Lokkerbol & Frederike Jörg & Ellen Visser & Robert A. Schoevers & Talitha L. Feenstra, 2021. "Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare," PharmacoEconomics, Springer, vol. 39(6), pages 721-730, June.
    • Handle: RePEc:spr:pharme:v:39:y:2021:i:6:d:10.1007_s40273-021-01012-x
    DOI: 10.1007/s40273-021-01012-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01012-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-021-01012-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. David Proudman & Paul Greenberg & Dave Nellesen, 2021. "The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers," PharmacoEconomics, Springer, vol. 39(6), pages 619-625, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:6:d:10.1007_s40273-021-01012-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.